Gaerolwe Masheto, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Isoniazid | 8 | 2024 | 274 | 0.710 |
Why?
|
| HIV Infections | 18 | 2024 | 16718 | 0.660 |
Why?
|
| Tuberculosis | 7 | 2024 | 1912 | 0.520 |
Why?
|
| Vascular Diseases | 1 | 2023 | 1161 | 0.490 |
Why?
|
| Anti-HIV Agents | 7 | 2023 | 4256 | 0.400 |
Why?
|
| Antitubercular Agents | 6 | 2024 | 1320 | 0.390 |
Why?
|
| Stillbirth | 2 | 2023 | 346 | 0.310 |
Why?
|
| Latent Tuberculosis | 2 | 2021 | 225 | 0.300 |
Why?
|
| Postpartum Period | 5 | 2023 | 1086 | 0.300 |
Why?
|
| Abortion, Spontaneous | 2 | 2024 | 544 | 0.280 |
Why?
|
| Pregnancy Outcome | 5 | 2024 | 2795 | 0.270 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2019 | 657 | 0.260 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2021 | 2026 | 0.250 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2023 | 215 | 0.220 |
Why?
|
| Benzoxazines | 2 | 2023 | 301 | 0.220 |
Why?
|
| E-Selectin | 1 | 2023 | 579 | 0.190 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2023 | 707 | 0.180 |
Why?
|
| Pregnancy | 13 | 2024 | 29144 | 0.180 |
Why?
|
| Alkynes | 1 | 2020 | 306 | 0.180 |
Why?
|
| Botswana | 1 | 2023 | 1040 | 0.180 |
Why?
|
| Oxazines | 1 | 2021 | 298 | 0.170 |
Why?
|
| Adenine | 2 | 2023 | 936 | 0.170 |
Why?
|
| Cyclopropanes | 1 | 2020 | 416 | 0.170 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2023 | 1155 | 0.170 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2019 | 2559 | 0.150 |
Why?
|
| Nystatin | 1 | 2017 | 23 | 0.150 |
Why?
|
| Rifampin | 1 | 2019 | 315 | 0.150 |
Why?
|
| Gentian Violet | 1 | 2017 | 31 | 0.150 |
Why?
|
| Candidiasis, Oral | 1 | 2017 | 60 | 0.150 |
Why?
|
| Viremia | 1 | 2020 | 736 | 0.140 |
Why?
|
| Pyridones | 1 | 2021 | 712 | 0.140 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2021 | 1320 | 0.130 |
Why?
|
| Birth Weight | 1 | 2023 | 2069 | 0.120 |
Why?
|
| Premature Birth | 2 | 2024 | 1721 | 0.120 |
Why?
|
| Placenta | 1 | 2023 | 1698 | 0.120 |
Why?
|
| Antifungal Agents | 1 | 2017 | 730 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2021 | 1832 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 1873 | 0.090 |
Why?
|
| Piperazines | 1 | 2021 | 2488 | 0.090 |
Why?
|
| Infant | 5 | 2024 | 35136 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 1715 | 0.080 |
Why?
|
| Mothers | 1 | 2019 | 2165 | 0.080 |
Why?
|
| Viral Load | 3 | 2023 | 3299 | 0.080 |
Why?
|
| Female | 17 | 2024 | 380194 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 3022 | 0.070 |
Why?
|
| HIV-1 | 1 | 2023 | 6939 | 0.070 |
Why?
|
| HIV | 2 | 2024 | 1604 | 0.060 |
Why?
|
| Tablets | 1 | 2023 | 145 | 0.060 |
Why?
|
| Dideoxynucleosides | 1 | 2023 | 122 | 0.060 |
Why?
|
| Lamivudine | 1 | 2023 | 342 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2024 | 25625 | 0.050 |
Why?
|
| Tuberculin Test | 1 | 2021 | 214 | 0.050 |
Why?
|
| Humans | 18 | 2024 | 744343 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2023 | 369 | 0.050 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2020 | 86 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2020 | 380 | 0.050 |
Why?
|
| Pregnancy Trimester, First | 1 | 2024 | 853 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 6489 | 0.040 |
Why?
|
| Alanine | 1 | 2021 | 572 | 0.040 |
Why?
|
| Young Adult | 6 | 2020 | 56430 | 0.040 |
Why?
|
| Adult | 10 | 2023 | 214055 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 528 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2020 | 615 | 0.040 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2019 | 406 | 0.040 |
Why?
|
| HIV Antibodies | 1 | 2023 | 1322 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2020 | 12026 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2020 | 1460 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2017 | 690 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2019 | 754 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 1978 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2021 | 3206 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2021 | 1695 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1590 | 0.030 |
Why?
|
| RNA | 1 | 2023 | 2749 | 0.030 |
Why?
|
| Gestational Age | 1 | 2021 | 3493 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2017 | 820 | 0.030 |
Why?
|
| Adolescent | 4 | 2021 | 85781 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 4933 | 0.020 |
Why?
|
| Child | 3 | 2023 | 77709 | 0.020 |
Why?
|
| Body Weight | 1 | 2020 | 4669 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2017 | 3913 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2019 | 2063 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9274 | 0.020 |
Why?
|
| Genotype | 1 | 2020 | 12951 | 0.020 |
Why?
|
| Prevalence | 1 | 2023 | 15226 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 53288 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2017 | 3209 | 0.010 |
Why?
|
| Male | 4 | 2023 | 350118 | 0.010 |
Why?
|
| United States | 1 | 2023 | 69872 | 0.010 |
Why?
|
| Middle Aged | 2 | 2020 | 213383 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 57776 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 63114 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 163280 | 0.000 |
Why?
|